San­doz joins up with B2B phar­ma to com­mer­cial­ize six biosim­i­lars in the US

No­var­tis sub­sidiary San­doz has joined up with B2B phar­ma Adal­vo in a dis­tri­b­u­tion and col­lab­o­ra­tion agree­ment for six un­named biosim­i­lar prod­ucts in the US, the com­pa­nies an­nounced Thurs­day.

San­doz now has the ex­clu­sive rights to com­mer­cial­ize the Adal­vo an­ti­fun­gals and an­tibi­otics, on­col­o­gy and pul­monary ther­a­peu­tics. The gener­ic and biosim­i­lar gi­ant ex­pects some of these launch­es to oc­cur in 2024 with a mar­ket size of around $3 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.